Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Knowing when to reassess your financial plan is key to success. Stay informed about the right times to make adjustments.
23,167 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Rivian’s quality metrics, limited service footprint, and steep pricing are prompting investor caution in 2026. This r...
JPMorgan Chase delivered a record quarterly performance, yet Jamie Dimon cautioned that the current market sprint cou...
More than 60 analysts now rate the stock Buy as investors await the upcoming earnings release and assess cloud, adver...
A new model from Google Gemini AI projects a bold Solana price target for 2026, highlighting infrastructure upgrades ...
Bittensor's TAO price prediction cycle returns as its AI-driven network expands, with new forecasts for 2025-2030 and...
Toll Brothers posted a strong first quarter, underscoring resilience in the luxury segment through disciplined execut...
The Supreme Court ruled against the tariff program but did not lay out a refunds plan. Officials say lower courts wil...
RAD Intel hits Nasdaq with the ticker $RADI after raising more than $50 million, marking a 4,900% valuation jump in f...
Coinbase stock has fallen sharply this year, yet a cadre of analysts believes a turnaround is possible as the company...
Synopsys topped earnings and revenue expectations as AI-fueled chip design demand remains strong. Yet softer Q2 guida...
A rumored $111 billion Paramount Warner Bros' deal could fuse studios, streaming, and networks under a private group,...